- Home
- NERV vs SYBX Comparison
NERV vs SYBX Comparison
Compare NERV & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- SYBX
- Stock Information
- Founded
- NERV 2007
- SYBX N/A
- Country
- NERV United States
- SYBX United States
- Employees
- NERV N/A
- SYBX N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- NERV Health Care
- SYBX Health Care
- Exchange
- NERV Nasdaq
- SYBX Nasdaq
- Market Cap
- NERV 15.5M
- SYBX 16.5M
- IPO Year
- NERV 2014
- SYBX N/A
- Fundamental
- Price
- NERV $1.82
- SYBX $1.36
- Analyst Decision
- NERV Hold
- SYBX Hold
- Analyst Count
- NERV 1
- SYBX 1
- Target Price
- NERV $5.00
- SYBX N/A
- AVG Volume (30 Days)
- NERV 77.1K
- SYBX 19.0K
- Earning Date
- NERV 03-04-2025
- SYBX 03-18-2025
- Dividend Yield
- NERV N/A
- SYBX N/A
- EPS Growth
- NERV N/A
- SYBX N/A
- EPS
- NERV N/A
- SYBX N/A
- Revenue
- NERV N/A
- SYBX $2,777,000.00
- Revenue This Year
- NERV N/A
- SYBX N/A
- Revenue Next Year
- NERV N/A
- SYBX N/A
- P/E Ratio
- NERV N/A
- SYBX N/A
- Revenue Growth
- NERV N/A
- SYBX 292.23
- 52 Week Low
- NERV $1.77
- SYBX $1.22
- 52 Week High
- NERV $7.53
- SYBX $2.04
- Technical
- Relative Strength Index (RSI)
- NERV 34.70
- SYBX 45.23
- Support Level
- NERV $1.77
- SYBX $1.31
- Resistance Level
- NERV $2.05
- SYBX $1.40
- Average True Range (ATR)
- NERV 0.16
- SYBX 0.07
- MACD
- NERV -0.04
- SYBX 0.00
- Stochastic Oscillator
- NERV 6.41
- SYBX 60.61
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.